Table 3.
Pharmacokinetic Parameters of Valacyclovir and Acyclovir in Wildtype and Bphl Knockout Mice after the Oral and Intravenous Administrations of 25 nmoL/g Valacyclovir
| Oral | Cmax (μM) |
Tmax (min) |
AUC0–180 (μM·min) |
T1/2 (min) |
|---|---|---|---|---|
| Wildtype | ||||
| VACV | 1.3 ± 0.6 | 5 ± 0 | 22.1 ± 6.5 | 48.9 ± 18.4 |
| ACV | 7.6 ± 0.6 | 15 ± 0 | 402 ± 126 | 47.5 ± 10.1 |
| VACV/ACV (%) | 17 ± 6 | 33 ± 0 | 5.5 ± 2.4 | 103 ± 1 |
| Bphl Knockout | ||||
| VACV | 2.0 ± 0.5 | 5 ± 0 | 38.3 ± 10.3 | 37.2 ± 2.6 |
| ACV | 9.4 ± 0.2* | 12 ± 3 | 419 ± 81 | 37.0 ± 6.6 |
| VACV/ACV(%) | 22 ± 2 | 43 ± 2* | 9.1 ± 3.0 | 100 ± 1 |
| Intravenous |
Cmax (μM) |
Tmax (min) |
AUC0–180 (μM·min) |
T1/2 (min) |
| Wildtype | ||||
| VACV | 9.1 ± 0.4 | 2 ± 0 | 109 ± 8 | 50.2 ± 15.4 |
| ACV | 6.8 ± 0.3 | 5 ± 0 | 259 ± 18 | 45.9 ± 6.0 |
| VACV/ACV(%) | 134 ± 1 | 40 ± 0 | 37.3 ± 3.9 | 109 ± 1 |
| Bphl Knockout | ||||
| VACV | 11.6 ± 0.5* | 2 ± 0 | 145 ± 11 | 53.7 ± 19.8 |
| ACV | 8.8 ± 2.6 | 12 ± 3 | 373 ± 97 | 37.3 ± 6.2 |
| VACV/ACV(%) | 131 ± 3 | 17 ± 2*** | 34.2 ± 9.3 | 144 ± 1*** |
*
p ≤ 0.05
***
p ≤ 0.001, as compared to wildtype mice for tde same route of administration, using an unpaired t-test.